Eli Lilly has provided new insights into retatrutide, its investigational medicine that is attracting significant attention for its potential to treat obesity, type 2 diabetes, and several obesity-related health conditions. While the therapy remains under clinical development and is not yet approved for public use, ongoing research suggests it could become one of the most impactful treatments in the rapidly growing obesity care market.

Researchers at Mass General Brigham have developed a promising blood test that could help physicians identify head and neck cancer patients at higher risk of disease recurrence and poorer survival outcomes, potentially enabling more personalized treatment strategies and follow-up care.

Merck has announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), as well as the newly approved subcutaneous formulation KEYTRUDA QLEx™, in combination with WELIREG® (belzutifan) for the adjuvant treatment of certain patients with renal cell carcinoma (RCC), the most common form of kidney cancer.

As healthcare delivery becomes increasingly team-oriented, pharmaceutical marketers are being encouraged to look beyond physicians and engage a broader network of healthcare professionals involved in patient care. According to a recent announcement from IQVIA Digital, artificial intelligence is helping marketers identify and connect with nurse practitioners (NPs), physician associates (PAs), and other key members of collaborative care teams who play a growing role in treatment decisions.